Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

Classification of Skeletal Muscle Relaxants

Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Outcomes of Microvascular Decompression for Young-Onset Trigeminal Neuralgia.

Neurosurgery·2026

Same author

Quantitative Sensory Testing Identifies Altered Thermal and Pain Processing in Trigeminal Neuralgia.

European journal of neurology·2026

Same author

Topical capsaicin 8% differentially blocks activation of nociceptors by mechanical, heat, and electrical stimuli in human skin.

Pain·2026

Same author

Exceptional long attenuation of chemically evoked itch and axon reflex flare after topical 8% capsaicin.

The Journal of investigative dermatology·2026

Same author

Muscle Ultrasound in Inclusion Body Myositis: Integrating Qualitative and Quantitative Approaches With Clinical and MRI Findings.

Muscle & nerve·2026

Same author

Neurocognitive Therapeutic Exercise Integrated with Focal Mechanical Vibrations in a CANVAS Patient: A Case Report.

Neurology international·2026

Search research articles

Related Experiment Video

Updated: May 29, 2026

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation

Published on: June 26, 2018

Treating pain in multiple sclerosis.

Andrea Truini¹, Francesca Galeotti, Giorgio Cruccu

¹University of Rome-La Sapienza, Department of Neurology and Psychiatry, Viale Università 30, 00185 Rome, Italy. cruccu@uniroma1.it

Expert Opinion on Pharmacotherapy

|September 16, 2011

Summary

This summary is machine-generated.

Managing pain in multiple sclerosis (MS) involves reviewing current literature and therapeutic options. Evidence-based knowledge guides practical treatment approaches for MS-related pain, considering drug side effects.

More Related Videos

Development of Recombinant Proteins to Treat Chronic Pain

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain

Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain

Published on: March 8, 2024

Related Experiment Videos

Last Updated: May 29, 2026

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation

Published on: June 26, 2018

Development of Recombinant Proteins to Treat Chronic Pain

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain

Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain

Published on: March 8, 2024

Area of Science:

Neurology
Pain Management
Pharmacology

Background:

Multiple sclerosis (MS) is a central nervous system disease characterized by inflammation and demyelination.
MS frequently leads to chronic pain conditions in patients.

Purpose of the Study:

To review current literature on therapeutic options for MS-related pain.
To provide evidence-based knowledge and practical guidance on treating MS pain.

Main Methods:

Comprehensive literature review of existing studies on MS pain management.
Analysis of therapeutic options, including drug dosing, titration, and side effects.

Main Results:

Cannabinoids are the only agents evaluated in randomized controlled trials for MS pain.
Concerns regarding abuse potential and psychiatric adverse events suggest cautious use of cannabinoids.

Conclusions:

Current treatment strategies for MS pain should align with general principles for peripheral neuropathic pain.
Careful consideration of drug-induced adverse effects is essential in managing MS-related pain.